Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
not_yet_recruitingphase_1

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

NCT07436858
recruiting

Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

NCT07114627

Clinical Trials (2)

Showing 2 of 2 trials
NCT07436858Phase 1

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Not Yet Recruiting
NCT07114627

Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
2